|HIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics|
AB Abecasis, AMJ Wensing, D Paraskevis, J Vercauteren, K Theys, ...
Retrovirology 10 (1), 7, 2013
|Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study|
J Gregson, M Tang, N Ndembi, RL Hamers, SY Rhee, VC Marconi, ...
The Lancet infectious diseases 16 (5), 565-575, 2016
|An integrated map of HIV genome-wide variation from a population perspective|
G Li, S Piampongsant, NR Faria, A Voet, AC Pineda-Peña, R Khouri, ...
Retrovirology 12 (1), 18, 2015
|The incidence of multidrug and full class resistance in HIV-1 infected patients is decreasing over time (2001–2006) in Portugal|
J Vercauteren, K Deforche, K Theys, M Debruyne, LM Duque, S Peres, ...
Retrovirology 5 (1), 12, 2008
|Genetic diversity and selective pressure in hepatitis C virus genotypes 1–6: significance for direct-acting antiviral treatment and drug resistance|
L Cuypers, G Li, P Libin, S Piampongsant, AM Vandamme, K Theys
Viruses 7 (9), 5018-5039, 2015
|CRF19_cpx is an evolutionary fit HIV-1 variant strongly associated with rapid progression to AIDS in Cuba|
V Kouri, R Khouri, Y Alemán, Y Abrahantes, J Vercauteren, ...
EBioMedicine 2 (3), 244-254, 2015
|Functional conservation of HIV-1 Gag: implications for rational drug design|
G Li, J Verheyen, SY Rhee, A Voet, AM Vandamme, K Theys
Retrovirology 10 (1), 126, 2013
|HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir|
K Theys, J Vercauteren, J Snoeck, M Zazzi, RJ Camacho, C Torti, ...
Antimicrobial agents and chemotherapy 57 (2), 1053-1056, 2013
|Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patients|
K Theys, K Deforche, J Vercauteren, P Libin, DAMC van de Vijver, J Albert, ...
Retrovirology 9 (1), 81, 2012
|HIV-1 genotypic drug resistance testing: digging deep, reaching wide?|
K Van Laethem, K Theys, AM Vandamme
Current opinion in virology 14, 16-23, 2015
|Tick-borne encephalitis virus triggers inositol-requiring enzyme 1 (IRE1) and transcription factor 6 (ATF6) pathways of unfolded protein response|
C Yu, K Achazi, M Niedrig
Virus research 178 (2), 471-477, 2013
|Modelled in vivo HIV fitness under drug selective pressure and estimated genetic barrier towards resistance are predictive for virological response|
K Deforche, A Cozzi-Lepri, K Theys, B Clotet, RJ Camacho, J Kjaer, ...
Antiviral therapy 13 (3), 399-407, 2008
|Covering all bases in HIV research: unveiling a hidden world of viral evolution.|
B Vrancken, S Lequime, K Theys, P Lemey
AIDS reviews 12 (2), 89-102, 2010
|RegaDB: community-driven data management and analysis for infectious diseases|
P Libin, G Beheydt, K Deforche, S Imbrechts, F Ferreira, K Van Laethem, ...
Bioinformatics 29 (11), 1477-1480, 2013
|Resistance pathways of human immunodeficiency virus type 1 against the combination of zidovudine and lamivudine|
K Theys, K Deforche, P Libin, RJ Camacho, K Van Laethem, ...
Journal of General Virology 91 (8), 1898-1908, 2010
|Assessing transmissibility of HIV-1 drug resistance mutations from treated and from drug-naive individuals|
R Winand, K Theys, M Eusébio, J Aerts, RJ Camacho, P Gomes, ...
AIDS (London, England) 29 (15), 2045, 2015
|HIV-1 gp120 N-linked glycosylation differs between plasma and leukocyte compartments|
YS Ho, AB Abecasis, K Theys, K Deforche, DE Dwyer, M Charleston, ...
Virology journal 5 (1), 14, 2008
|Within-patient mutation frequencies reveal fitness costs of CpG dinucleotides and drastic amino acid changes in HIV|
K Theys, AF Feder, M Gelbart, M Hartl, A Stern, PS Pennings
PLoS genetics 14 (6), 2018
|The impact of HIV-1 within-host evolution on transmission dynamics|
K Theys, P Libin, AC Pineda-Pena, A Nowe, AM Vandamme, AB Abecasis
Current opinion in virology 28, 92-101, 2018
|Mapping the genomic diversity of HCV subtypes 1a and 1b: Implications of structural and immunological constraints for vaccine and drug development|
L Cuypers, G Li, C Neumann-Haefelin, S Piampongsant, P Libin, ...
Virus evolution 2 (2), 2016